Investment Analysts’ Weekly Ratings Updates for Lumexa Imaging (LMRI)

Several brokerages have updated their recommendations and price targets on shares of Lumexa Imaging (NASDAQ: LMRI) in the last few weeks:

• 10/5/2026 – Lumexa Imaging is now covered by Truist Financial Corporation. They set a “buy” rating and a $18.00 price target on the stock.
• 10/3/2026 – Lumexa Imaging was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/28/2026 – Lumexa Imaging was given a new $17.00 price target by Raymond James Financial, Inc..
• 9/28/2026 – Lumexa Imaging had its “strong-buy” rating reaffirmed by UBS Group AG.
• 9/24/2026 – Lumexa Imaging is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/24/2026 – Lumexa Imaging is now covered by KeyCorp. They set an “overweight” rating and a $18.00 price target on the stock.
• 9/22/2026 – Lumexa Imaging had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 9/12/2026 – Lumexa Imaging was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/28/2026 – Lumexa Imaging had its price target raised by Barclays PLC from $9.00 to $13.00. They now have an “overweight” rating on the stock.
• 8/16/2026 – Lumexa Imaging was upgraded by Wall Street Zen from “hold” to “buy”.

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.